Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Leukemia, Myeloid, Acute 23Myelodysplastic Syndromes 6Myeloproliferative Disorders 5Glioma 5Cholangiocarcinoma 5Leukemia 3Wilms Tumor 2Sarcoma, Ewing 2Sarcoma 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Recurrence 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Neoplasm Metastasis 2Medulloblastoma 2Lymphoma, Non-Hodgkin 2Histiocytosis, Langerhans-Cell 2Hepatoblastoma 2Hematologic Neoplasms 2Ependymoma 2Chondrosarcoma 2Biliary Tract Neoplasms 2Xanthogranuloma, Juvenile 1Pancreatic Ductal Adenocarcinoma 1Neoplasms, Unknown Primary 1Neoplasm, Residual 1Lymphoma, Follicular 1IDH1-Mutated Malignancies 1

Interventions

ivosidenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × IDH1 Mutation Myeloid Neoplasms × ivosidenib × Clear all
NCT03564821 2025-11-04

IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation

Massachusetts General Hospital

Phase 1 Completed
18 enrolled
Myeloid

IDH1 Mutation Myeloid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡